Compare Mercadolibre Inc (MELI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Twist Bioscience Corp — how do they compare? Mercadolibre Inc trades at $1,871.95 (market cap $94.13B), while Twist Bioscience Corp trades at $165.44 (market cap $10.08B). The key difference: Mercadolibre Inc is far larger — about 9.3× Twist Bioscience Corp's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and Twist Bioscience Corp for 27 Days on average.
| MELI | TWST | |
|---|---|---|
Market Cap | $94.13B | $10.08B |
Volume | 273,781 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $205.00 |
52-Week Low | $1.55K | $25.45 |
Typical Hold Time | 117 Days | 27 Days |
Enterprise Value | $101.77B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,868.01, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin compressed to 6.91%. Recent news highlights expansion in Brazil's delivery and pharmacy segments, while analyst consensus remains strongly bullish with a $2,170 price target.
MELI's integrated e-commerce and fintech ecosystem in Latin America presents significant growth potential, supported by expanding credit portfolios and advertising revenue. Key risks include macroeconomic pressures in Argentina and margin compression from increased investment. With 73% analyst buy ratings and institutional accumulation, the stock offers growth exposure but requires monitoring of profitability trends.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
